Brief: Paion: US FDA Approval Of Remimazolam For Induction And Maintenance Of Procedural Sedation

PAION AG

03/07/2020 07:32

July 3 (Reuters) - Paion AG  PA8G.DE :
    * SAID ON THURSDAY U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVO)
FOR
THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION
    * PAION WILL RECEIVE A MILESTONE PAYMENT OF EUR 15 MILLION
FROM
COSMO AND TIERED ROYALTIES ON NET SALES RANGING FROM 20% TO 25%

Source text for Eikon:  ID:nEQ1GN5Kfa 
Further company coverage:  PA8G.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))